Marlise Luskin, M.D.

Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• 401 - Host, treatment, and disease-related risk factors for invasive fungal disease in 549 patients with newly diagnosed high-risk myeloid malignancies treated with intensive induction chemotherapy

  Tuesday, October 21, 2025
  2:45 PM - 2:57 PM US ET